{"id":405591,"date":"2020-12-24T16:10:10","date_gmt":"2020-12-24T21:10:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=405591"},"modified":"2020-12-24T16:10:10","modified_gmt":"2020-12-24T21:10:10","slug":"rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/","title":{"rendered":"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA"},"content":{"rendered":"

<\/p>\n

ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA<\/b><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–
\nRosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.\n<\/p>\n

\nOn November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma\u2019s \u201cunaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020 should no longer be relied upon.\u201d Sonoma continued that the financial statements for this time period \u201ccontained material errors\u201d and that \u201cthe Company will need to restate them.\u201d\n<\/p>\n

\nOn this news, Sonoma\u2019s share price fell $1.10 per share, or more than 14%, over the next few trading days to close at $6.63 per share on November 20, 2020.\n<\/p>\n

\nRosen Law Firm is preparing a securities lawsuit on behalf of Sonoma shareholders. If you purchased securities of Sonoma please visit the firm\u2019s website at http:\/\/www.rosenlegal.com\/cases-register-1992.html<\/a> to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com<\/a> or cases@rosenlegal.com<\/a>.\n<\/p>\n

\nFollow us for updates on LinkedIn: https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a> or on Twitter: https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: https:\/\/www.facebook.com\/rosenlawfirm<\/a>.\n<\/p>\n

\nRosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm\u2019s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.\n<\/p>\n

\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201224005217\/en\/<\/a><\/span><\/p>\n

\nLaurence Rosen, Esq.
\n
Phillip Kim, Esq.
\n
The Rosen Law Firm, P.A.
\n
275 Madison Avenue, 40th<\/sup> Floor
\n
New York, NY 10016
\n
Tel: (212) 686-1060
\n
Toll Free: (866) 767-3653
\n
Fax: (212) 202-3827
\n
lrosen@rosenlegal.com
\n<\/a>
<\/span>pkim@rosenlegal.com
\n<\/a>
<\/span>cases@rosenlegal.com<\/a>
<\/span>www.rosenlegal.com<\/a><\/p>\n

KEYWORDS:<\/b> New York United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Legal Professional Services<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA NEW YORK–(BUSINESS WIRE)– Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma\u2019s \u201cunaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020 should no longer be relied upon.\u201d Sonoma continued that the financial statements for this time period \u201ccontained material errors\u201d and that \u201cthe Company will need … <\/p>\n

Continue reading “ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-405591","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA NEW YORK–(BUSINESS WIRE)– Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma\u2019s \u201cunaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020 should no longer be relied upon.\u201d Sonoma continued that the financial statements for this time period \u201ccontained material errors\u201d and that \u201cthe Company will need … Continue reading "ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-24T21:10:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201224005217r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA\",\"datePublished\":\"2020-12-24T21:10:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\\\/\"},\"wordCount\":422,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201224005217r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\\\/\",\"name\":\"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201224005217r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-12-24T21:10:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201224005217r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201224005217r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/","og_locale":"en_US","og_type":"article","og_title":"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA - Market Newsdesk","og_description":"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA NEW YORK–(BUSINESS WIRE)– Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma\u2019s \u201cunaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020 should no longer be relied upon.\u201d Sonoma continued that the financial statements for this time period \u201ccontained material errors\u201d and that \u201cthe Company will need … Continue reading \"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-24T21:10:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201224005217r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA","datePublished":"2020-12-24T21:10:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/"},"wordCount":422,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201224005217r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/","name":"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201224005217r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-12-24T21:10:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201224005217r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201224005217r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rosen-a-leading-investor-firm-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc-snoa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. \u2013 SNOA"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/405591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=405591"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/405591\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=405591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=405591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=405591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}